Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Solid Tumor Metastatic Cancer Advanced Cancer Unresectable Solid Neoplasm The study population consists of adult patients with advanced solid tumors that meet all of the following to be enrolled into this study: 1. Age ≥ 18 years. 2. Patients with histologically confirmed solid tumors with a likelihood of expression of GNX102 targeted antigens, which are limited to colorectal hepatocellular non-small cell lung gastric breast bladder pancreatic melanoma (cutaneous, acral, or mucosal) esophageal  Patients who meet any of the following will be excluded from participation in this study: 1. Has any other malignancy not listed in # 2. 2. Has a positive PCR test for active COVID-19 infection or has signs or symptoms consistent with COVID-19 in the absence of a negative PCR test. 3. Has New York Heart Association Class III or IV heart disease. 4. History of myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, within the past 6 months. 5. History of cerebral vascular accident or transient ischemic attack within the past 6 months. 6. History of primary CNS tumor. 7. History of CNS metastases, unless previously treated and stable for at least 4 weeks in the absence of steroids. Patients with meningeal carcinomatosis are excluded regardless of treatment. 8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy within 72 hours of start of therapy. 9. Active, nonmalignant GI disease requiring treatment (such as inflammatory bowel disease, Crohn's disease, colitis) that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, which would make the patient inappropriate for entry into this study. 10. Clinical symptoms of pancreatitis within the past 28 days. 11. Known active infection with HIV, hepatitis B (HBV), or hepatitis C (HCV) Patients with a history of HBV or HCV are allowed if HBV DNA or HCV RNA are undetectable. Patients with hepatocellular cancer on anti-viral therapy must have DNA levels ≤ 500 IU/ml Patients with a history of HBV or HCV will be monitored for reactivation while on study. 12. Pregnant or nursing women. 13. Treatment with radiation therapy within 14 days prior to dosing with GNX102. 14. Major surgery within 14 days prior to dosing with GNX102. 15. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia. 16. No second malignancy which is considered active or requires concurrent treatment. 17. For patients with hepatocellular carcinoma Ascites requiring more than 1 paracentesis per month History of hepatic encephalopathy within 12 months of study entry. 18. History of bleeding esophageal or gastric varices within 6 months of study entry. 19. Prior or ongoing cancer treatment, including investigational treatment within 5 half-lives or 21 days whichever is less, prior to dosing with GNX102 and 6 weeks for nitrosoureas or mitomycin C. 20. Allergies to any excipients in GNX102 (i.e., L-histidine, sucrose, Polysorbate 80). 21. Severe acute or chronic medical or psychiatric conditions or other laboratory abnormalities that would impart, in the judgment of the investigator and/or sponsor, excess risk associated with study participation or study drug administration, which would make the patient inappropriate for entry into this study